2017 FDLI Annual Conference
May 4, 2017

Axinn partner Chad Landmon spoke on a panel entitled, "Key Regulatory Issues in Biosimilars," at FDLI's Annual Conference in Washington, DC. Panelists discussed the latest regulatory issues surrounding FDA approval standards for biosimilars and the latest legal developments relating to the BPCIA's "patent dance."

Click here to access Chad's presentation. 

By using the Axinn, Veltrop & Harkrider LLP website with cookies enabled on your browser, you agree to our use of cookies during your browsing experience. Learn more about our privacy policy.